Business Description
ABIVAX is a French biotech company founded in 2013 that works on treatments for long-term inflammatory conditions such as ulcerative colitis and Crohn's disease. Its main drug, obefazimod, is currently being tested in late-stage clinical trials. The company operates by targeting the body's own immune system to reduce harmful inflammation in affected patients.
